In a large cohort of 630 pediatric patients age < 21 years with de novo AML, FLT3-ITD was detected in 12% of patients (age 0.6–19.8 years) and FLT-ALM in 6.7% (age 0.3–19.7 years) [117]. This evidence concerns the gene FLT3 and acute myeloid leukemia.